0001193125-25-270123
SEC filingClearPoint Neuro's Q3 2025 revenue rose 9% YoY to $8.86M, gross margin improved to 63%, but net loss widened to $5.89M on higher interest expense and operating costs.
For Q3 2025, ClearPoint Neuro reported total revenue of $8.86M, a 9% increase from $8.12M in Q3 2024. Growth was driven by service revenue (+32%) and neurosurgery navigation (+20%), partially offset by a -1% decline in biologics revenue. Gross profit rose 16% to $5.60M, with gross margin expanding to 63% from 60%, attributed to higher-margin biologics services and product mix. Operating expenses increased across all categories: R&D (+4% to $3.45M), sales & marketing (+8% to $3.84M), and G&A (+14% to $3.59M). Net interest expense swung from income of $0.21M to expense of $0.54M due to a new note payable in May 2025. Consequently, net loss widened 18% to $5.89M.
Management did not provide quantitative guidance but noted expectations to continue incurring losses as they invest in commercialization and platform expansion. Existing cash of $38.2M is deemed sufficient for at least 12 months. Key factors include partner trial progression, adoption of new products (SmartFrame OR, Prism Laser), and macroeconomic conditions. The increase in partner count provides a tailwind for future biologics revenue, although near-term visibility remains limited due to trial timing.
As of September 30, 2025, ClearPoint Neuro reported cash and cash equivalents of $38.2M, a significant increase from $20.1M at December 31, 2024, primarily driven by the $28.7M net proceeds from the May 2025 note issuance. Total assets rose to $60.4M, while total liabilities grew to $44.5M (up from $13.8M), largely due to the new $29.2M long-term note payable (net). Stockholders' equity decreased to $15.9M from $25.4M, reflecting accumulated losses of $209.1M. The company remains in a net loss position, with an operating loss of $17.1M for the first nine months of 2025. Despite these losses, management asserts that existing cash is sufficient for at least the next twelve months.
The company has operating lease commitments for facilities in Solana Beach (expiring 2026), Carlsbad (through 2033), and a new San Diego lease (11-year term starting 2025). Aggregate lease costs were $0.8M for the nine months ended September 30, 2025. No material purchase commitments for inventory or supply are disclosed. A legal settlement in August 2025 was covered by insurance and had no material impact.
No share buybacks or dividends were declared. The primary capital allocation event was the issuance of a $30M principal note (First Purchase Note) under a $105M facility, with net proceeds of $28.7M after discounts and costs. The note bears variable interest (minimum 8.25%, capped 9.50%) and includes a revenue participation feature starting in 2027. Capital expenditures were $473k for the nine months, primarily for property and equipment. The company also entered into an ATM equity facility (up to $50M) but has not utilized it.
ClearPoint Neuro operates as a single reportable segment. However, revenue is disaggregated into three service lines: Biologics and drug delivery ($13.8M for 9M 2025, +5.9% YoY), Neurosurgery navigation and therapy ($10.1M, +37.4% YoY), and Capital equipment and software ($2.6M, -18.3% YoY). All operations are U.S.-based. The CODM uses consolidated net income as the primary performance measure, with no allocation of segment assets or profit.
Cash flow from operations (CFO) was -$11.8M, more negative than net loss of -$17.8M due to non-cash addbacks: share-based compensation ($6.2M), depreciation/amortization ($0.6M), PIK interest ($0.5M), and RO asset amortization ($0.8M). Working capital provided a net $2.4M inflow (receivables down $0.5M, inventory down $0.0M, payables/accruals down $1.3M, etc.). CFO remains negative, indicating core operations still cash-consuming. Capital intensity is low (capex/sales not shown but $0.5M). No FCF or capital returns disclosed. Financing activity drove $30.6M inflow, primarily from a $28.7M note payable (net of costs) and $3.3M equity offerings. The company relied on external funding to cover cash burn. The cash balance increased $18.3M to $38.4M. Anomalies: significant increase in share-based comp and PIK interest, and large financing proceeds masking operating shortfall.